



Personalis, Inc. to Present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019

October 24, 2019

MENLO PARK, Calif.--(BUSINESS WIRE)--Oct. 24, 2019--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019 in Boston, October 27-30, including a poster presentation on October 27th.

The [poster presentation](#), titled "A comprehensive, highly accurate genomics platform for precision immunotherapy: Simultaneously characterize tumors and the TME from a single FFPE sample," will describe the Personalis universal cancer immunogenomics platform, [ImmunoID NeXT™](#). The poster will provide an overview of how the platform can be used to explore critical immunotherapy-related biomarkers of resistance and response; utilizing analytics including: human leukocyte antigen (HLA) typing and HLA loss of heterozygosity (LOH), neoantigen prediction and load, immune repertoire characterization, oncoviral detection, immune cell deconvolution, as well as the evaluation of tumor mutational burden (TMB) and microsatellite instability (MSI) status.

[ImmunoID NeXT™](#) is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.

The presentation will be delivered by Robert Power, M.S., Product Manager.

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The company's [NeXT™ Platform](#) is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis [Clinical Laboratory](#) is GxP aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter ([@PersonalisInc](https://twitter.com/PersonalisInc)).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191024005302/en/>

Source: Personalis, Inc.

Investor Relations Contact for Personalis:

Caroline Corner

investors@personalis.com

www.westwicke.com

415-202-5678

Media Contact for Personalis:

Jennifer Havlek

pr@personalis.com

www.personalis.com

650-752-1300